Former Shire execs set up shop to take a shot at 'under the radar' cancer target

Natalie Grover

Reporter

In December 2016, Shire abandoned a cancer drug targeting oxMIF it had swallowed as part of its $32 billion buyout of Baxalta earlier that year. Now former executives of the two companies have set up their own shop in Austria — banking on that same target.

The company, christened OncoOne, has scored €13 million in a Series A round. With 8 employees, including its 3 founders, the company will use the injection to take its compounds — designed to address pancreatic, colorectal, lung and ovarian cancer — into the clinic by 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Former Shire execs set up shop to take a shot at 'under the radar' cancer target

Natalie Grover

Reporter

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

For­mer Shire ex­ecs set up shop to take a shot at 'un­der the radar' can­cer tar­get

Natalie Grover

Reporter

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

Former Shire execs set up shop to take a shot at 'under the radar' cancer target

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them